| Inflammation in neurodegenerative diseases S Amor, F Puentes, D Baker, P Van Der Valk Immunology 129 (2), 154-169, 2010 | 1563 | 2010 |
| Cannabinoids control spasticity and tremor in a multiple sclerosis model D Baker, G Pryce, JL Croxford, P Brown, RG Pertwee, JW Huffman, ... Nature 404 (6773), 84-87, 2000 | 802 | 2000 |
| Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B. 1.617. 2) compared with alpha (B. 1.1. 7) variants of concern: a cohort study KA Twohig, T Nyberg, A Zaidi, S Thelwall, MA Sinnathamby, S Aliabadi, ... The Lancet Infectious Diseases 22 (1), 35-42, 2022 | 801 | 2022 |
| Inflammation in neurodegenerative diseases–an update S Amor, LAN Peferoen, DYS Vogel, M Breur, P van der Valk, D Baker, ... Immunology 142 (2), 151-166, 2014 | 590 | 2014 |
| Plasma β-amyloid in Alzheimer’s disease and vascular disease S Janelidze, E Stomrud, S Palmqvist, H Zetterberg, D Van Westen, ... Scientific reports 6 (1), 26801, 2016 | 561 | 2016 |
| Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain L Cristino, L De Petrocellis, G Pryce, D Baker, V Guglielmotti, V Di Marzo Neuroscience 139 (4), 1405-1415, 2006 | 561 | 2006 |
| The therapeutic potential of cannabis D Baker, G Pryce, G Giovannoni, AJ Thompson The Lancet Neurology 2 (5), 291-298, 2003 | 547 | 2003 |
| Identification of epitopes of myelin oligodendrocyte glycoprotein for the induction of experimental allergic encephalomyelitis in SJL and Biozzi AB/H mice. S Amor, N Groome, C Linington, MM Morris, K Dornmair, MV Gardinier, ... Journal of immunology (Baltimore, Md.: 1950) 153 (10), 4349-4356, 1994 | 491 | 1994 |
| Endocannabinoids control spasticity in a multiple sclerosis model D Baker, G Pryce, JL Croxford, P Brown, RG Pertwee, A Makriyannis, ... The FASEB journal 15 (2), 300-302, 2001 | 488 | 2001 |
| Plasma tau in Alzheimer disease N Mattsson, H Zetterberg, S Janelidze, PS Insel, U Andreasson, ... Neurology 87 (17), 1827-1835, 2016 | 467 | 2016 |
| Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors AI Idris, RJ van't Hof, IR Greig, SA Ridge, D Baker, RA Ross, SH Ralston Nature medicine 11 (7), 774-779, 2005 | 453 | 2005 |
| In silico patent searching reveals a new cannabinoid receptor D Baker, G Pryce, WL Davies, CR Hiley Trends in pharmacological sciences 27 (1), 1-4, 2006 | 446 | 2006 |
| Cannabinoids inhibit neurodegeneration in models of multiple sclerosis G Pryce, Z Ahmed, DJR Hankey, SJ Jackson, JL Croxford, JM Pocock, ... Brain 126 (10), 2191-2202, 2003 | 427 | 2003 |
| Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells K Maresz, G Pryce, ED Ponomarev, G Marsicano, JL Croxford, LP Shriver, ... Nature medicine 13 (4), 492-497, 2007 | 426 | 2007 |
| Two years later: journals are not yet enforcing the ARRIVE guidelines on reporting standards for pre-clinical animal studies D Baker, K Lidster, A Sottomayor, S Amor PLoS biology 12 (1), e1001756, 2014 | 316 | 2014 |
| Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal … D Baker, D Butler, BJ Scallon, JK O'Neill, JL Turk, M Feldmann European journal of immunology 24 (9), 2040-2048, 1994 | 309 | 1994 |
| Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis J Greenwood, CE Walters, G Pryce, N Kanuga, E Beraud, D Baker, ... FASEB journal: official publication of the Federation of American Societies …, 2003 | 298 | 2003 |
| MicroRNA-155 negatively affects blood-brain barrier function during neuroinflammation. MA Lopez-Ramirez, D Wu, G Pryce, JE Simpson, A Reijerkerk, ... FASEB journal 28 (6), 2551-2565, 2014 | 268 | 2014 |
| Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis D Baker, M Marta, G Pryce, G Giovannoni, K Schmierer EBioMedicine 16, 41-50, 2017 | 256 | 2017 |
| Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab D Baker, SS Herrod, C Alvarez-Gonzalez, G Giovannoni, K Schmierer JAMA neurology 74 (8), 961-969, 2017 | 223 | 2017 |
